Renal Solutions Inc

Renal Solutions Completes $16.5 M Series B Financing and Will Present at the SG Cowen Health Care Conference

Warrendale, PA, March 8, 2005 – Renal Solutions, Inc., the innovative provider of advanced sorbent hemodialysis products and services, announced today that it closed a $16.5 million Series B financing round. The round was led by new investors Triathlon Medical Ventures and PA Early Stage Partners, who were joined by several current investors including Birchmere Ventures, Blue Chip Venture Company, and Draper Triangle Ventures.

"This financing provides us with the capital necessary to introduce the Allient® Sorbent Hemodialysis System to the acute and chronic dialysis markets and to conduct clinical trials for the home market once we receive FDA approval," said Peter M. DeComo, Chairman and CEO of Renal Solutions. "We are very pleased with this vote of confidence from our anchor investors and delighted to welcome our new investors."

Suzette Dutch, Managing Partner of Triathlon Medical Ventures, said, "We believe Renal Solutions’ innovative technology and strong management team are poised to provide attractive returns by transforming the clinical care model for patients affected by renal failure. We look forward to working with the entire investor group to further assist the successful commercialization of this revolutionary technology."

It was also announced that Renal Solutions will present at the SG Cowen & Co. 25th Annual Health Care Conference on Tuesday, March 15, 2005, 8:30 AM, at The Boston Marriott Copley Place in Boston, MA. Mr. DeComo will present an overview of the Company and its plans for the commercialization of the Allient System. The conference will host over 250 companies highlighting some of the most attractive investment opportunities in the health care sector.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for company products/services and delays with respect to market acceptance. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Contact:

Media Inquiries:
Jennifer Bannan
Zero to Five, LLC
(412) 580-3675
jen@0to5.com

Commercial Inquires:
Sue Bentley
Marketing Director, Renal Solutions, Inc.
(724) 772-6900 ext. 109
sue.bentley@renalsolutionsinc.com

About Renal Solutions, Inc

Renal Solutions, Inc., a medical device and healthcare service company, is commercializing the Allient® Sorbent Hemodialysis System, a revolutionary technology/service solution for the chronic and acute dialysis market. The Allient System, brings SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) therapy to the dialysis field, opening new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1½ gallons of ordinary potable tap water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased flexibility and convenience benefits.